Trial Profile

An Open-label, Multicenter, Phase 1 Study to Evaluate Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Sep 2024 According to a TC BioPharm media release, company plans to execute the clinical trial in 2024 and into 2025.
19 Jun 2024 Status changed from planning to not yet recruiting.
06 May 2024 According to a TC BioPharm media release, company announced exercise of warrants for 3.1 million gross proceeds which will be used to support this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com